Sinorda Biomedicine is a China-based biopharmaceutical company focused on developing therapies for diseases of the digestive tract, tumor immunology/oncology, and immune-mediated disorders. The company advances both biologics and small-molecule candidates from discovery through clinical development, with a particular emphasis on antibody-based modalities.
Sinorda Biomedicine operates through a combination of in-house R&D and external collaborations with research and manufacturing partners to support preclinical studies, clinical trial supply, and potential commercialization. Its pipeline targets unmet needs in gastrointestinal and autoimmune conditions, with programs progressing across early- and mid-stage development for domestic and international markets.
